GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Integrated Diagnostics Holdings PLC (OTCPK:IDGXF) » Definitions » Net Cash per Share

Integrated Diagnostics Holdings (Integrated Diagnostics Holdings) Net Cash per Share : $-0.10 (As of Mar. 2024)


View and export this data going back to 2019. Start your Free Trial

What is Integrated Diagnostics Holdings Net Cash per Share?

Net Cash per Share is calculated as Cash, Cash Equivalents, Marketable Securities minus Total Liabilities minus Minority Interest and then divided by Shares Outstanding (EOP). Integrated Diagnostics Holdings's Net Cash per Share for the quarter that ended in Mar. 2024 was $-0.10.

The historical rank and industry rank for Integrated Diagnostics Holdings's Net Cash per Share or its related term are showing as below:

IDGXF's Price-to-Net-Cash is not ranked *
in the Medical Diagnostics & Research industry.
Industry Median: 6.7
* Ranked among companies with meaningful Price-to-Net-Cash only.

Integrated Diagnostics Holdings Net Cash per Share Historical Data

The historical data trend for Integrated Diagnostics Holdings's Net Cash per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Integrated Diagnostics Holdings Net Cash per Share Chart

Integrated Diagnostics Holdings Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Net Cash per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only -0.09 -0.11 -0.14 -0.16 -0.12

Integrated Diagnostics Holdings Quarterly Data
Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Dec23 Mar24
Net Cash per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.16 -0.13 -0.12 -0.12 -0.10

Competitive Comparison of Integrated Diagnostics Holdings's Net Cash per Share

For the Diagnostics & Research subindustry, Integrated Diagnostics Holdings's Price-to-Net-Cash, along with its competitors' market caps and Price-to-Net-Cash data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Integrated Diagnostics Holdings's Price-to-Net-Cash Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Integrated Diagnostics Holdings's Price-to-Net-Cash distribution charts can be found below:

* The bar in red indicates where Integrated Diagnostics Holdings's Price-to-Net-Cash falls into.



Integrated Diagnostics Holdings Net Cash per Share Calculation

In the calculation of a company's Net Cash per Share, assets other than cash and short term investments are considered to be worth nothing. But the company has to pay its debt and other liabilities in full. This is an extremely conservative way of valuation. Most companies have negative Net Cash per Share. But sometimes a company's price may be lower than its net-cash.

Integrated Diagnostics Holdings's Net Cash per Share for the fiscal year that ended in Dec. 2023 is calculated as

Net Cash per Share (A: Dec. 2023 )
=(Cash, Cash Equivalents, Marketable Securities-Total Liabilities-Minority Interest)/Shares Outstanding (EOP)
=(27.838-86.362-13.648)/600
=-0.12

Integrated Diagnostics Holdings's Net Cash per Share for the quarter that ended in Mar. 2024 is calculated as

Net Cash per Share (Q: Mar. 2024 )
=(Cash, Cash Equivalents, Marketable Securities-Total Liabilities-Minority Interest)/Shares Outstanding (EOP)
=(21.797-68.142-16.278)/600
=-0.10

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Integrated Diagnostics Holdings  (OTCPK:IDGXF) Net Cash per Share Explanation

Ben Graham invested in situations where the company's stock price was lower than its net-cash. He assigned some value to the company's other current asset. The value is called Net Current Asset Value (NCAV). One research study, covering the years 1970 through 1983 showed that portfolios picked at the beginning of each year, and held for one year, returned 29.4 percent, on average, over the 13-year period, compared to 11.5 percent for the S&P 500 Index. Other studies of Graham's strategy produced similar results.

You can find companies that are traded below their Net Current Asset Value (NCAV) with our Net-Net screener.


Integrated Diagnostics Holdings Net Cash per Share Related Terms

Thank you for viewing the detailed overview of Integrated Diagnostics Holdings's Net Cash per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


Integrated Diagnostics Holdings (Integrated Diagnostics Holdings) Business Description

Traded in Other Exchanges
Address
12 Castle Street, Saint Helier, JEY, JE2 3RT
Integrated Diagnostics Holdings PLC is active in the healthcare sector. It is a fully integrated diagnostics service provider. It is a fully integrated diagnostics service provider operating through brands such as Al Borg and Al Mokhtabar in Egypt, as well as Biolab in Jordan and Ultralab and Al Mokhtabar Sudan in Sudan. The company specializes in diagnostic tests, ranging from basic tests, such as glucose testing for diabetes, to molecular tests for hepatitis and specialized DNA tests. The company operates in two segment- Contract Segment and Walk-in Segment. It derives majority of its revenue from services offered in Egypt.

Integrated Diagnostics Holdings (Integrated Diagnostics Holdings) Headlines

From GuruFocus

Equity Portfolio as a Savings Account

By Steven CHEN 09-24-2021